Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.5390 -0.0310 (-5.44%)

Streaming Delayed Price Updated: 12:00 PM EST, Feb 12, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	473,785
Open	0.5800
Bid (Size)	0.5366 (200)
Ask (Size)	0.5390 (200)
Prev. Close	0.5700
Today's Range	0.5350 - 0.5800
52wk Range	0.5028 - 5.140
Shares Outstanding	9,362,444
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Today 10:12 EST

From Bernstein Liebhard LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

February 10, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Performance

YTD	-20.6%	-20.6%
1 Month	-23.4%	-23.4%
3 Month	-86.8%	-86.8%
6 Month	-81.6%	-81.6%
1 Year	-80.0%	-80.0%

More News

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 10, 2026

From Schall Law

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 06, 2026

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

February 05, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding The Upcoming Lead Plaintiff Deadline for the Filed Class Action Lawsuit

February 04, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

February 04, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

February 04, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

February 04, 2026

From Vistagen

Via Business Wire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 03, 2026

From Schall Law

Via GlobeNewswire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

February 02, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Class Action Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

January 30, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

January 29, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

January 29, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

January 28, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

January 27, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 27, 2026

From Schall Law

Via GlobeNewswire

Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit

January 26, 2026

From Robbins LLP

Via Business Wire

VISTAGEN CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

January 24, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit

January 24, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

January 23, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

January 22, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

January 20, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VTGN Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit

January 20, 2026

From Robbins LLP

Via GlobeNewswire

VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the Firm

January 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?

Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?

Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?

The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market

What is the current price of Vistagen Therapeutics, Inc. - Common Stock?

The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.5390

When was Vistagen Therapeutics, Inc. - Common Stock last traded?

The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 02/12/26 12:00 PM ET

What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?

The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 5.05M

How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?

Vistagen Therapeutics, Inc. - Common Stock has 5M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.